Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress

Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical... | May 20, 2023

Related Keywords

China ,Oregon ,United States ,Czech Republic ,Prague ,Praha ,Hlavníesto ,Fadyi Malik ,Ahmad Masri ,Diane Weiser ,Corporate Communications ,Us Food Drug Administration ,Hypertrophic Cardiomyopathy Center ,York Heart Association ,Facebook ,Globenewswire Inc ,Exchange Commission ,Oregon Health Science University ,International Congress ,European Society Of Cardiology ,Linkedin ,National Medical Products Administration ,Youtube ,Cytokinetics Incorporated ,Twitter ,Cytokinetics Incorporated Nasdaq ,Research Development ,Statistically Significant Improvements ,Angina Frequency ,High Sensitivity Troponin ,Randomized Evaluation ,Dosing With ,Obstructive Outflow Disease ,Late Breaking Clinical Trial ,Heart Failure ,Cytokinetic Executive Vice President ,Science University ,Kansas City Cardiomyopathy Questionnaire ,Clinical Symptom Score ,Breakthrough Therapy Designation ,Drug Administration ,Medical Products Administration ,Private Securities Litigation Reform Act ,Safe Harbor ,Vice President ,Cytokinetics ,Incorporated Stock Exchange ,News ,Information ,Press Release ,Treatment ,F ,Aficamten ,Gas ,End ,Ssociated ,Ith ,Statistically ,Significant ,Improvements ,N ,Angina ,Pyha ,Troponin , ,Hase , Cytk Us23282w6057 ,